Merz Patent-Cliff Exposure & CMS Drug Spending Portfolio

Merz (US): 3 reconciled FDA prescription therapies, $75.6M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2033-01-01
2024 CMS Total Public Spend$75.6M
2024 Medicare Part D Spend$68.1M
2024 Medicaid Spend$7.5M
California HCAI SB 17 Filings8 WAC filings (max 32.5% 2-yr change)